Ratings Hefei Lifeon Pharmaceutical Co., Ltd.

Equities

003020

CNE100004BD9

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
23.46 ^CNY	-1.01%		-7.71%	-16.66%

Apr. 29	Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company returns high margins, thereby supporting business profitability.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HEFEI LIFEON PHARMACEUTICAL CO., LTD.	-16.66%	524M	-
ELI LILLY AND COMPANY	+32.09%	694B	C+
NOVO NORDISK A/S	+29.39%	593B	B
JOHNSON & JOHNSON	-1.34%	371B	C+
MERCK & CO., INC.	+20.34%	331B	B-
ABBVIE INC.	+7.39%	290B	C+
ASTRAZENECA PLC	+14.25%	239B	B+
ROCHE HOLDING AG	-3.03%	209B	A+
NOVARTIS AG	+10.02%	209B	B-
AMGEN INC.	+8.49%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes